These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 19635282)
21. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Bork K; Gül D; Hardt J; Dewald G Am J Med; 2007 Nov; 120(11):987-92. PubMed ID: 17976427 [TBL] [Abstract][Full Text] [Related]
22. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Bork K; Meng G; Staubach P; Hardt J Transfusion; 2005 Nov; 45(11):1774-84. PubMed ID: 16271103 [TBL] [Abstract][Full Text] [Related]
23. Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2). Krassilnikova S; Craig ET; Craig TJ Expert Rev Clin Immunol; 2010 May; 6(3):327-34. PubMed ID: 20441418 [TBL] [Abstract][Full Text] [Related]
24. Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. Tallroth GA Int Arch Allergy Immunol; 2011; 154(4):356-9. PubMed ID: 20975289 [TBL] [Abstract][Full Text] [Related]
25. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Hofstra JJ; Kleine Budde I; van Twuyver E; Choi G; Levi M; Leebeek FW; de Monchy JG; Ypma PF; Keizer RJ; Huitema AD; Strengers PF Clin Immunol; 2012 Mar; 142(3):280-90. PubMed ID: 22197071 [TBL] [Abstract][Full Text] [Related]
26. [Recombinant human C1-inhibitor is effective in the treatment of acute attacks of hereditary angioedema--case report]. Porebski G; Bilo B; Obtułowicz K; Obtułowicz P; Nuijens J Przegl Lek; 2005; 62(5):317-20. PubMed ID: 16334540 [TBL] [Abstract][Full Text] [Related]
27. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. Waytes AT; Rosen FS; Frank MM N Engl J Med; 1996 Jun; 334(25):1630-4. PubMed ID: 8628358 [TBL] [Abstract][Full Text] [Related]
28. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Craig TJ; Rojavin MA; Machnig T; Keinecke HO; Bernstein JA Ann Allergy Asthma Immunol; 2013 Sep; 111(3):211-5. PubMed ID: 23987198 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Riedl MA; Levy RJ; Suez D; Lockey RF; Baker JW; Relan A; Zuraw BL Ann Allergy Asthma Immunol; 2013 Apr; 110(4):295-9. PubMed ID: 23535096 [TBL] [Abstract][Full Text] [Related]
31. Molecular diagnosis and management of hereditary angioedema in a Greek family. Papadopoulou-Alataki E; Foerster T; Antari V; Pavlitou-Tsiontsi A; Varlamis G Int Arch Allergy Immunol; 2008; 147(2):166-70. PubMed ID: 18535392 [TBL] [Abstract][Full Text] [Related]
32. Hereditary angioedema and pregnancy. Chinniah N; Katelaris CH Aust N Z J Obstet Gynaecol; 2009 Feb; 49(1):2-5. PubMed ID: 19281571 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Martinez-Saguer I; Rusicke E; Aygören-Pürsün E; von Hentig N; Klingebiel T; Kreuz W Transfusion; 2010 Feb; 50(2):354-60. PubMed ID: 19788511 [TBL] [Abstract][Full Text] [Related]
34. Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema. Riedl MA; Lumry WR; Li HH; Craig TJ; Fitts D; Kalfus I; Uknis ME Am J Rhinol Allergy; 2013; 27(6):517-21. PubMed ID: 24274230 [TBL] [Abstract][Full Text] [Related]
35. Treatment with C1-inhibitor concentrate does not induce IgM type anti-C1 inhibitor antibodies in patients with hereditary angioedema. Varga L; Füst G; Csuka D; Farkas H Mol Immunol; 2011 Jan; 48(4):572-6. PubMed ID: 21111483 [TBL] [Abstract][Full Text] [Related]
36. Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. Farkas H; Csuka D; Zotter Z; Szabó E; Czaller I; Varga L; Fejes J; Füst G; Harmat G J Allergy Clin Immunol; 2013 Mar; 131(3):909-11. PubMed ID: 23063583 [No Abstract] [Full Text] [Related]
37. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. Gadek JE; Hosea SW; Gelfand JA; Santaella M; Wickerhauser M; Triantaphyllopoulos DC; Frank MM N Engl J Med; 1980 Mar; 302(10):542-6. PubMed ID: 7351888 [TBL] [Abstract][Full Text] [Related]
38. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate naïve patients. Varga L; Széplaki G; Visy B; Füst G; Harmat G; Miklós K; Németh J; Cervenak L; Karádi I; Farkas H Mol Immunol; 2007 Feb; 44(6):1454-60. PubMed ID: 16750855 [TBL] [Abstract][Full Text] [Related]
39. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Choi G; Soeters MR; Farkas H; Varga L; Obtulowicz K; Bilo B; Porebski G; Hack CE; Verdonk R; Nuijens J; Levi M Transfusion; 2007 Jun; 47(6):1028-32. PubMed ID: 17524093 [TBL] [Abstract][Full Text] [Related]
40. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Bork K; Bygum A; Hardt J Ann Allergy Asthma Immunol; 2008 Feb; 100(2):153-61. PubMed ID: 18320917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]